Merck & Company, Inc. (NYSE:MRK)‘s stock had its “hold” rating reissued by equities researchers at Deutsche Bank AG in a research report issued on Monday. They currently have a $66.00 price objective on the stock, up from their prior price objective of $64.00. Deutsche Bank AG’s price objective would suggest a potential upside of 5.41% from the stock’s previous close.
Other equities research analysts have also issued research reports about the company. Vetr lowered Merck & from a “strong-buy” rating to a “buy” rating and set a $69.99 target price on the stock. in a research report on Wednesday, May 17th. Jefferies Group LLC reiterated a “sell” rating and issued a $51.00 target price on shares of Merck & in a research report on Wednesday, May 24th. Zacks Investment Research lowered Merck & from a “buy” rating to a “hold” rating in a research report on Thursday, May 25th. BMO Capital Markets reiterated a “buy” rating and issued a $74.00 target price on shares of Merck & in a research report on Tuesday, June 27th. Finally, Citigroup Inc. set a $65.00 price target on Merck & and gave the company a “hold” rating in a report on Wednesday, July 5th. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $69.63.
Shares of Merck & (MRK) traded down 0.71% during trading on Monday, hitting $62.61. 7,387,313 shares of the stock traded hands. The firm has a market cap of $171.25 billion, a price-to-earnings ratio of 39.90 and a beta of 0.81. The stock has a 50 day moving average of $64.44 and a 200 day moving average of $63.36. Merck & has a 52-week low of $57.18 and a 52-week high of $66.80.
Merck & (NYSE:MRK) last issued its earnings results on Tuesday, May 2nd. The company reported $0.88 EPS for the quarter, beating the Zacks’ consensus estimate of $0.83 by $0.05. The firm had revenue of $9.43 billion for the quarter, compared to analyst estimates of $9.25 billion. Merck & had a return on equity of 24.99% and a net margin of 15.32%. Merck &’s revenue for the quarter was up 1.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.89 earnings per share. Analysts expect that Merck & will post $3.85 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Merck & Company, Inc. (MRK) Receives “Hold” Rating from Deutsche Bank AG” was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.com-unik.info/2017/07/17/merck-company-inc-nysemrk-given-new-66-00-price-target-at-deutsche-bank-ag.html.
In related news, Director C Robert Kidder sold 5,000 shares of the stock in a transaction on Friday, May 12th. The stock was sold at an average price of $63.54, for a total value of $317,700.00. Following the completion of the transaction, the director now directly owns 14,317 shares of the company’s stock, valued at approximately $909,702.18. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.05% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. HM Capital Management LLC increased its position in Merck & by 0.4% in the first quarter. HM Capital Management LLC now owns 3,734 shares of the company’s stock valued at $236,000 after buying an additional 15 shares in the last quarter. RB Capital Management LLC increased its position in Merck & by 0.5% in the second quarter. RB Capital Management LLC now owns 4,587 shares of the company’s stock valued at $294,000 after buying an additional 23 shares in the last quarter. Bath Savings Trust Co increased its position in Merck & by 0.5% in the second quarter. Bath Savings Trust Co now owns 5,427 shares of the company’s stock valued at $348,000 after buying an additional 28 shares in the last quarter. City Holding Co. increased its position in Merck & by 0.4% in the first quarter. City Holding Co. now owns 7,767 shares of the company’s stock valued at $494,000 after buying an additional 31 shares in the last quarter. Finally, Camelot Portfolios LLC increased its position in Merck & by 0.4% in the first quarter. Camelot Portfolios LLC now owns 7,771 shares of the company’s stock valued at $494,000 after buying an additional 33 shares in the last quarter. 73.76% of the stock is owned by hedge funds and other institutional investors.
Merck & Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
What are top analysts saying about Merck & Company Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Merck & Company Inc. and related companies.